OHRP +17% on SPA for phase-3 Squalamine trial in wet AMD: http://finance.yahoo.com/news/ohr-pharmaceutical-inc-announces-spa-110000764.html Caution: OHRP is proceeding to phase-3 despite missing the primary endpoint in phase-2—see #msg-112155291 for background.